Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2025, titled "Zydus receives USFDA Fast Track Designation for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis (ALS)".